As of 11:15:40 AM EDT. Market Open.

The severity of CTOR's downturn is underscored by additional InvestingPro data showing a 3-month price total return of -87.76%, closely mirroring the article's reported 87.37% decline over the past ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Fintel reports that on September 23, 2025, Maxim Group upgraded their outlook for Citius Oncology (NasdaqCM:CTOR) from Hold to Buy. As of September 13, 2025, the average one-year price target for ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Citius Oncology ( (CTOR)) has issued an ...

Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand ...

) has been revised to $6.12 / share. This is an increase of 100.00% from the prior estimate of $3.06 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.